首页> 美国卫生研究院文献>Scientific Reports >Survival improvement in patients with pancreatic cancer by decade: A period analysis of the SEER database 1981–2010
【2h】

Survival improvement in patients with pancreatic cancer by decade: A period analysis of the SEER database 1981–2010

机译:十年后胰腺癌患者的生存改善:SEER数据库的期间分析1981-2010年

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pancreatic cancer (PaCa) is an aggressive malignancy with a high mortality rate and a poor prognosis. To evaluate treatment outcomes of patients with pancreatic cancer over the past three decades, data from the Surveillance, Epidemiology, and End Results (SEER) registries were used to assess the survival of patients with PaCa. A total of 63,530 patients diagnosed with pancreatic cancer between 1981 and 2010 were identified from nine original SEER registries. The 1-year relative survival rates (RSRs) improved each decade, from 17.0% to 19.9% to 28.2% (p < 0.0001), with a larger increase during the third decade than during the second decade. However, the long-term survival rates have remained very low. The 5-year RSRs increased from 3.1% to 4.4% to 6.9% over these three decades—i.e., still only few patients with PaCa survive more than 5 years. Furthermore, our analysis demonstrated that the survival rates for all the patients with pancreatic cancer were lower in patients of lower socioeconomic status and black race. These results will help predict future trends in PaCa incidence and survival, contribute to better-designed clinical trials by eliminating disparities that may affect the results, and thereby improve the clinical management and outcomes of PaCa.
机译:胰腺癌(PaCa)是一种恶性肿瘤,死亡率高,预后差。为了评估过去三十年来胰腺癌患者的治疗结果,使用了来自监测,流行病学和最终结果(SEER)注册表的数据来评估PaCa患者的生存率。从9个原始SEER注册表中识别出1981年至2010年之间总计63,530例被诊断为胰腺癌的患者。每十年的1年相对生存率(RSR)从17.0%提高到19.9%,再提高到28.2%(p <0.0001),在第三个十年中比在第二个十年中增长更大。但是,长期存活率仍然很低。在这三个十年中,五年期RSR从3.1%增加到4.4%,再上升到6.9%,即,仍然只有少数PaCa患者存活超过5年。此外,我们的分析表明,在社会经济地位较低和黑人种族较低的患者中,所有胰腺癌患者的存活率均较低。这些结果将有助于预测PaCa发生率和生存率的未来趋势,通过消除可能影响结果的差异,从而有助于设计更好的临床试验,从而改善PaCa的临床管理和疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号